Anti-IgE monoclonal antibody medication for treating asthma and allergy. Brand name Xolair. 1. FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma - June 2003 article on the drug's US approval. Includes information about results of clinical trials. 2. The Johns Hopkins Gazette: May 10, 1999 - Article about clinical testing of the experimental anti-allergy agent Anti-IgE, in a version called rhuMAb-E25. 3. Xolair - Full prescribing information from RxList. 4. Xolair: New Hope for Asthma and Allergy Sufferers - Article about this medication under development by Genentech, from Vanderbilt University. 5. Xolair - FamilyDoctor.org - Information for patients in English or Spanish.

Help build the largest human-edited directory on the web. Submit a Site - Update a Site - Open Directory Project - Become an Editor

© 2008 Chamas Enterprises Inc.